Allos Pharma
Pharmaceutical Manufacturing • • 1-10 Employees
Company overview
| Headquarters | XX |
| Website | |
| NAICS | 3254 |
| Founded | 2020 |
| Employees | 1-10 |
| Socials |
Key Contact at Allos Pharma
Mads Emil Matthiesen
Co-founder, Board Director
About Allos Pharma
We are a global team dedicated to improve the lives of patients with Fragile X Syndrome and Autism Spectrum Disorder. Our work spans three decades of research in neuroscience and intellectual disabilities. The “mGluR theory of fragile X” proposed by MIT Professor Mark Bear and collaborators in 2004 is widely considered to be a key conceptual breakthrough, and laid the foundation for development of disease-modifying therapies for treatment of Fragile X Syndrome and Autism Spectrum Disorder. Allos Pharma is committed to develop and market the first approved therapy in Fragile X Syndrome. The name Allos Pharma is derived from allistic, meaning not autistic.
Allos Pharma revenue & valuation
| Annual revenue | $171,110 |
| Revenue per employee | $86,000 |
| Estimated valuation?This valuation is estimated based on industry average for the Pharmaceutical Manufacturing industry and current estimated revenues | $547,552 |
| Total funding | No funding |
Employees by Management Level
Total employees: 1-10
Seniority
Employees
Employees by Department
Allos Pharma has 1 employees across 1 departments.
Departments
Number of employees
Allos Pharma Tech Stack
Discover the technologies and tools that power Allos Pharma's digital infrastructure, from frameworks to analytics platforms.
Web servers
Miscellaneous
JavaScript libraries
Caching
UI frameworks
Programming languages
Font scripts
Blogs
Form builders
Analytics
Databases
Page builders
United Kingdom
France
United States
Canada
EstoniaFrequently asked questions
4.8
40,000 users
